Analgesia with fentanyl and midazolam during interventional radiologic liver tumor ablation by catheter-based radiotherapy-safety and risk factors.

Recruiting

• Conditions: C22.0; C78.7; Liver cell carcinoma; Secondary malignant neoplasm of liver and intrahepatic bile duct

• Registration Number: DRKS00032468
• Lead Sponsor: MU München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Patients who have undergone local ablation therapy with catheter-based radiotherapy under analgesia for one or more liver tumors.

Exclusion Criteria

Patients who have not undergone local ablation therapy with catheter-based radiotherapy under analgesia due to one or more liver tumors.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Of all identified patients who received catheter-based radiotherapy for liver tumors, age, gender, BMI, ASA, comorbidities, smoking history, procedural characteristics (duration of procedure, volume irradiated, number of catheters), dose of fentanyl/midazolam, and procedural co-factors (bleeding, allergic reaction) documented after the primary procedure will be collected and analyzed anonymously. July 01, 2017 marks the date of establishment of catheter-based radiotherapy at LMU Hospital.

Secondary Outcome Measures

Name	Time	Method
Vital Sign Fluctuation (SpO2 <90% and/or BP reduction of 20% from baseline) is considered a potential event.